Sign Out
Adverse reactions from Olmesartan medoxomil in clinical trials, post-authorisation safety studies and spontaneous reporting are summarized in the table as follows.
The following terminologies have been used in order to classify the occurrence of adverse reactions: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000). (See table.)
Click on icon to see table/diagram/image
View ADR Reporting Link
Continue with Google